The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series E | Dead

Total Raised


Last Raised


About CoMentis

CoMentis is focused on developing drugs to treat various central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company covers the research and development spectrum from initial drug design through manufacturing and clinical trials.

CoMentis Headquarter Location

400 Oyster Point Blvd. Suite 226

South San Francisco, California, 94080,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CoMentis Patents

CoMentis has filed 6 patents.

patents chart

Application Date

Grant Date


Related Topics




Nicotinic antagonists, Ion channels, Nicotinic acetylcholine receptors, Nicotinic agonists, Stimulants


Application Date


Grant Date



Related Topics

Nicotinic antagonists, Ion channels, Nicotinic acetylcholine receptors, Nicotinic agonists, Stimulants



Latest CoMentis News

Tenet joins forces with Comentis to boost client vulnerability support for advisers

Jan 18, 2022

Tenet Compliance Services (TCS) has further strengthened its support for Directly Authorised advisers by introducing a financial vulnerability identification and reporting solution from growing fintech firm Comentis. Fully aligned to the FCA’s drivers of vulnerability, the solution enables TCS advisers to consistently identify, support, and record vulnerable client activity through a clinically developed assessment process […] The post Tenet joins forces with Comentis to boost client vulnerability support for advisers appeared first on Fintech Finance.

  • When was CoMentis founded?

    CoMentis was founded in 2004.

  • Where is CoMentis's headquarters?

    CoMentis's headquarters is located at 400 Oyster Point Blvd., South San Francisco.

  • What is CoMentis's latest funding round?

    CoMentis's latest funding round is Series E.

  • How much did CoMentis raise?

    CoMentis raised a total of $82.19M.

  • Who are the investors of CoMentis?

    Investors of CoMentis include Sanderling Ventures, Life Science Angels, Clarus, Astellas Venture Management, Medicxi Ventures and 6 more.

  • Who are CoMentis's competitors?

    Competitors of CoMentis include Humanetics Corporation, Annovis Bio, Hyperion Therapeutics, Neuronascent, iPierian, IVERIC bio, KAI Pharmaceuticals, Mithridion, CGI Pharmaceuticals, Corixa and 19 more.

You May Also Like


Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

OTO Medicine

OtoMedicine, Inc. aims to become a provider of medicines to prevent, treat and cure hearing loss. Based on over two decades of research at the University of Michigan, the company's lead product, AuraquellTM, is a combination of micronutrients that significantly aims to reduce noise induced hearing loss (NIHL) suffered by individuals continually exposed to loud noise in their work or recreational activities.


Metastatix is a pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Per the company, Metastatix has pioneered the development of a series of oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.